Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000

Journal of Clinical Psychiatry

Volumn 63, Issue 4, 2002, Pages 288-299

  Suppes, Trisha ^a   Dennehy, Ellen B ^a   Swann, Alan C ^a   Bowden, Charles L ^a   Calabrese, Joseph R ^a   Hirschfeld, Robert M A ^a   Keck Jr , Paul E ^a   Sachs, Gary S ^a   Lynn Crismon, M ^a   Toprac, Marcia G ^a   Shon, Steven P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZALKONIUM CHLORIDE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRANYLCYPROMINE; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ALGORITHM; CONFERENCE PAPER; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HEALTH CARE ORGANIZATION; HUMAN; HYPOMANIA; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MENTAL HEALTH SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES;

EID: 0036240660     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v63n0404     Document Type: Conference Paper

References (107)

1. Texas Medication Algorithm Project: Definitions, rationale, and methods to develop medication algorithms
2. The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder
3. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder
4. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
5. Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project
6. Texas Medication Algorithm Project: Development and feasibility testing of a treatment algorithm for patients with bipolar disorder
7. The manic syndrome: Factors which may predict a patient's response to lithium, carbamazepine and valproate
8. The relationship between anti-manic agent for treatment of classic or dysphoric mania and length of hospital stay
9. Depression during mania: Treatment response to lithium or divalproex
10. Efficacy of divalproex vs lithium and placebo in the treatment of mania
11. Valproate in the treatment of acute mania: A placebo-controlled study
12. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study
13. Olanzapine versus placebo in the treatment of acute mania
14. Efficacy of olanzapine in acute bipolar mania
15. Olanzapine compared to lithium in mania: A double-blind randomized controlled trial
16. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
17. Hyperglycemia associated with the use of atypical antipsychotics
18. Antipsychotic-induced weight gain: A review of the literature
19. Association of diabetes mellitus with atypical neuroleptics
20. Mood stabilizer combinations: A review of safety and efficacy
21. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study
22. Psychotropic drug prescription patterns among patients with bipolar I disorder
23. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs
24. Medication algorithms for bipolar disorder
25. The Expert Consensus Guideline Series: Medication treatment of bipolar disorder 2000
26. Risperidone compared with both lithium and haloperidol in mania: A double-blind randomized controlled trial
27. Efficacy and tolerability of risperidone versus placebo in combination with lithium or valproate in acute mania
28. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders
29. Risperidone in the treatment of mania
30. Acute treatment of bipolar disorder with adjunctive risperidone in outpatients
31. Long-term risperidone treatment in bipolar disorder: 6-month follow up
32. Place of newer antiepileptic drugs in the treatment of epilepsy
33. New anti-epileptic drugs for the 21st century
34. Acute anti-manic efficacy and safety of oxcarbazepine in an open trial with an on-off-on design
35. Oxcarbazapine and divalproex sodium: A comparison of efficacy and side effects for mania
36. Studies with oxcarbazepine (Trileptal) in acute mania
37. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders
38. Carbamazepine and oxcarbazepine in the treatment of manic syndromes: Studies in Germany
39. Effect of oxcarbazepine on affective and schizo-affective symptoms: A preliminary report
40. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis
41. Comparison of oxcarbazepine and carbamazepine: A double-blind study
42. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy
43. Therapeutic effects of carbamazepine in affective illness: A preliminary report
44. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study
45. Carbamazepine versus lithium in mania: A double-blind study
46. Carbamazepine compared with lithium in the treatment of mania
47. Lithium combined with carbamazepine or haloperidol in the treatment of mania
48. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder
49. The use of quetiapine for treatment-resistant bipolar disorder: A case series
50. Quetiapine fumarate in neuroleptic-dependent mood disorders
51. Quetiapine for treatment-resistant mania
52. Clinical predictors of acute response with quetiapine in psychotic mood disorders
53. Clinical response to quetiapine addon for treatment refractory bipolar disorder
54. Quetiapine as adjunctive treatment for adolescent mania
55. Ziprasidone in the acute treatment of mania: A double-blind, placebo-controlled, randomized trial
56. Electroconvulsive treatment compared with lithium in the management of manic states
57. Electroconvulsive therapy of acute manic episode: A review of 50 years' experience
58. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia
59. Is clozapine a mood stabilizer?
60. Clozapine in bipolar disorder: Treatment implications for other atypical antipsychotics
61. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania
62. Topiramate as add-on treatment for patients with bipolar mania
63. Mood stabilization and weight loss with topiramate [letter]
64. Treatment of acute mania with topiramate [letter]
65. Open-label adjunctive topiramate in the treatment of bipolar disorders
66. A pilot study of topiramate as monotherapy in the treatment of acute mania
67. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design
68. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder
69. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder
70. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
71. Lamotrigine for the treatment of bipolar disorder: A clinical case series
72. Lamotrigine compared with lithium in mania: A double-blind randomized controlled trial
73. The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV
74. Clinical and research implications of the diagnosis of dysphoric or mixed mania or hypomania
75. Clinical picture and etiologic models of mixed states
76. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders
77. Incidence of co-occurrence of hypomania and depressive symptoms in the Stanley Foundation Bipolar Network
78. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression
79. Can antidepressants cause mania and worsen the course of affective illness?
80. Antidepressant-induced mania and cycle acceleration: A controversy revisited
81. Long-term stability of polarity distinctions in the affective disorders
82. Treatment of bipolar depression, a review of the literature and a suggestion for an algorithm
83. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder
84. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression
85. A double-blind trial of bupropion versus desiprarnine for bipolar depression
86. An open study of lamotrigine in refractory bipolar depression
87. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
88. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
89. Prophylactic efficacy of lithium carbonate in manic-depressive illness: Report of the Veterans Administration and National Institute of Mental Health collaborative study group
90. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients
91. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients
92. Alternative approaches to refractory depression in bipolar illness
93. Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies
94. A novel augmentation strategy for treating resistant major depression
95. Tranylcypromine versus imipramine in anergic bipolar depression
96. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression
97. Addition of monoamine oxidase inhibitors to carbamazepine: Preliminary evidence of safety and anti-depressant efficacy in treatment-resistant depression
98. Omega 3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial
99. The efficacy of acupuncture in the treatment of major depression in women
100. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants
101. Controlled trials in bipolar I depression: Focus on switch rates and efficacy
102. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder
103. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders
104. Nice guidelines for investigating efficacy in bipolar disorder
105. Results from the Texas Medication Algorithm Project (TMAP) Bipolar Disorder Treatment Module